Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

The BiovaxID Phase 3 clinical trial is being conducted at fourteen U.S. oncology centers and 8 centers in Russia.

Applications for accelerated conditional approval of BiovaxID are planned to be submitted to both the Food and Drug Administration (FDA) and European Medicines Agency (EMEA) by mid-2008. The DMC has agreed to serve as a liaison between the Company and the FDA and the EMEA. If conditionally approved, BiovaxID could become commercially available in early 2009.

Members of the investment community, the media, and other interested parties can access the PowerPoint presentation and an audio webcast by visiting Accentia's homepage at www.accentia.net, or for audio only, http://www.wsw.com/webcast/jeff18/abpi. The PowerPoint presentation and audio will be available and archived on Accentia's website for 90 days.

About Biovest International, Inc.

Biovest International, Inc., is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ:ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID(TM), which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. For further information, visit the Company Web site at www.biovest.com.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. and its subsidiaries (collectively referred to as the "Company"
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action

Post Your Comments:
(Date:11/6/2009)...ESTBURY, N.Y., Nov. 6 Repossession...ne tools in the third quarter of 2009 declined as ...o Nassau Asset Management,s NasTrac Quarterly Inde...ctivity reports for both repossessions and orderly...ons for both construction and printing equipment, ...
(Date:11/6/2009)...RINCETON, N.J., Nov. 6 ..., a provider of advanced wound care products, anno...lts before market on Monday, November 16, 2009. Th...y to discuss the results at 11:00 am EST. Interest...r (857) 350-1684 (international), with passcode 81...
(Date:11/6/2009)...URRYSVILLE, Pa., Nov. 6 Philips Re...Disease Control and Prevention (CDC) to raise awar...ronic sleep insufficiency. The CDC,s release of th...state differences in sleeplessness is a milestone ... ,, As a long-time educator, industry leader an...
Breaking Medicine Technology:NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Statement by Don Spence, CEO, Philips Home Healthcare Solutions, Endorsing CDC Educational Initiatives to Raise Awareness of Sleep Deprivation 2Slimbolics Signs Marketing Contract for Its Revolutionary Weight Loss Aid 54032 1Slimbolics Signs Marketing Contract for Its Revolutionary Weight Loss Aid 54032 2Jim Deal Appointed to MedCaths Board of Directors 54027 1Jim Deal Appointed to MedCaths Board of Directors 54027 2California Cryobank Names Richard Jennings President of FamilyCord Division 4838 1California Cryobank Names Richard Jennings President of FamilyCord Division 4838 2
...ponse Rate to Combination Treatment, FRAZER, Pa.,...today that in a phase 2 study published online tod... of patients with relapsed indolent,B-cell and man... treatment,with TREANDA(R) (bendamustine hydrochlo...on study is one of three studies in patients with ...
...14 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) tod... program to evaluate MAP0004 as a potential treatm...self-administered at home using MAP,Pharmaceutical...prior Phase,2 efficacy study, MAP0004 provided pai...ained through at least 24 hours. The study also,de...
Other Medicine Technology:Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 2Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 3Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 4Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkin's Lymphoma 5MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 2MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 3MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine 4
(Date:11/7/2009)...to stem a growing problem across the U.S. , ...lf of students at four-year colleges do it regular...ing -- downing five or more alcoholic drinks at a ...cohol as a drug," said Jenny Hwang, associate dean... at Stony Brook University on Long Island, N.Y. In...
(Date:11/7/2009)... In the current economic climate, many Ameri...are only spending money on what that they consider...urgeon David D. Kim believes that it’s very...to receive treatment to improve their health, and ...e to patients in this tough economy by offering re...
(Date:11/7/2009)... A new foot spray from Greensations fights p...t peppers and caffeine. ThermaFeet targets foot pa...at also contains Black Walnut, Goldenseal, Vitamin... Schenectady, NY (PRWEB) November 7, 2009 -- A...increases circulation with the power of hot pepper...
(Date:11/6/2009)...ecently a Narconon of Georgia graduate was feature...rescription drug abuse. The special report focused...iction . In the report Andrew shared his near de...done to prevent prescription drug abuse. ,, "I wok...ned my eyes to my father on top of me giving me CP...
(Date:11/6/2009)...ouse health bill loaded with pledge-breaking tax h...leased today by Americans for Tax Reform: ,, By ...ay, President Barack Obama effectively announced t... lie. ,, During the campaign, Obama made a "firm ...milies making less than $250,000 per year: ,, "I...
Breaking Medicine News(10 mins):Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 2Health News:Binge Drinking Puts the Brain, and Life Itself, at Risk 3Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 3Health News:Hot Peppers and Caffeine Relieve Painful Feet, Toe Fungus and Foot Odor 2Health News:Narconon Drug Rehab of Georgia Graduate Featured on Local News 2Health News:ATR: Obama Lied, His Tax Pledge Died 2Health News:ATR: Obama Lied, His Tax Pledge Died 3
...tudying a rare inherited syndrome, researchers at ...rogram themselves to turn down their own energy-m...e changes might help cancer cells survive and spre...rhouses of the cell that consume oxygen to generat...
...ohns Hopkins Childrens Center neurologists are sou...hat children dont suffer strokes. In fact, nearl... year, and half of them end up with permanent neur...cer, sadly, strokes in children are sometimes not ...
...bu Dhabi will soon have the world's first zero-car...enewable energy resources. According to WA... create an eco friendly city was officially launc...sdar and the Abu Dhabi Future Energy Company (ADFE...
...he shocking story of medical negligence that led t...has moved the Delhi High Court to ask the concerne... a fractured leg brought Jai to the government-run...tach, necessitating its surgical separation on Mar...
... 15-year-old Indian-American boy underwent a simul... in New Delhi, which the attending doctors claimed...-based Ganesh Nehru was suffering from a disease k...ents suffering from the disease usually die by the...
...eceiving daily steroid treatment has been found be...strophy. A new study has found that daily intake ...longer period of time and reduce their risk of sco... ability to walk between ages nine and 11. There i...
Other Medicine News:Health News:Cancer Cells Reprogram Energy Needs To Grow And Spread 2Health News:Childhood Strokes Linked to Whiplash, Other Traumatic Injury 2Health News:Abu Dhabi to Have Worlds First Zero-carbon City 2Health News:Court Seeks Explanation from Hospital for Childs Amputation 2Health News:NRI Boy Underwent a Rare Dual Transplant Surgery 2Health News:Daily Steroids Helpful for Boys Down With Muscular Dystrophy 2
...g; and Zyplast® injectable collagen implants h...hing facial lines, wrinkles and scars and in provi...the skins natural collagen, require minimal proced...re than one million people worldwide have been tre...
Captique™ Hyaluronic Acid Dermal Filler
...ge of non-surgical facial contouring materials. Yo... results for various applications with exceptional...fers superior versatility for a wide variety of no... Long-lasting, Radiesse saves time and money for b...
HEMOCHRON Model 401 Coagulation Monitoring Instrument
Medicine Products: